Q4 Presentation 2022

We create value and contribute to improved quality of life in Life Science

2

MedCap | An active investor in Life Science companies

MedTech Business Area

Sales by Segment (MSEK)

Geographies

5%

36%

20%

Sweden

Nordic

1 111

50%

Europe

64%

25%

RoW

Specialty Pharma Business Area

Employees

368

Listed on Stockholm

Nasdaq Mid Cap

MedTech Specialty Pharma

3

Highlights Q4

  • Sales growth by 25%
  • Strong demand and good performance in both business areas
  • EBITDA increased by 16% excluding one-time effects of 3.3 mSEK last year
  • EBITDA-marginof 23% which is 1 ppt lower after excluding one-time effects last year
  • Solid balance sheet; Net Debt / EBITDA ratio
    • IFRS16: 0.4 (0.8)
    • Excl IFRS16: -0.2(-0.1)
  • Acquisition of AdderaCare (finalized in Q1 '23)

Q4 2022

Net Sales

322.8

+25%

(MSEK)

EBITDA

73.3

+10%

(MSEK)

EBITDA-

22.7%

-3.1 ppt

margin

4

Sales and EBITDA by quarter

Net sales per quarter (MSEK)

+25%

350

284

323

300

258

263

242

227

223

233

250

188

200

186

211

206

201

202

200

183

173

166

175

160

150

100

50

0

Q1

Q2

Q3

Q4

Q1 *

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

18

19

20

EBITDA per quarter (MSEK)

+16%

80

73

63

70

56

59

60

50

50

50

46

41

38

37

41

38

40

36

27

31

30

30

22

19

20

17

20

10

0

Q1

Q2

Q3

Q4

Q1 *

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

18

19

20

  • Excluding one-time effects in 2021 and 2022
  • IFRS16 incl. from Q1 2019

Q4

YTD

Net Sales growth

+25%

+21%

EBITDA growth

+16%

+27%

EBITDA-margin

23%

21%

Excluding one-time effects

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

MedCap AB published this content on 10 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 February 2023 05:46:03 UTC.